Esperion agrees to $1.1 billion ARCHIMED buyout

Esperion ( (ESPR) ) just unveiled an announcement.

On May 1, 2026, Esperion announced a definitive agreement under which funds managed by healthcare-focused private equity firm ARCHIMED will acquire the company in an all-cash transaction valued at up to about $1.1 billion. The deal will see shareholders receive $3.16 per share in cash, a 58% premium to the April 30 close, plus one non-tradeable contingent value right per share that could yield up to $100 million in aggregate milestone payments tied to U.S. net sales of bempedoic acid and bumetanide products.

The merger, unanimously approved by Esperion’s board and backed by committed debt financing from Pharmakon-managed funds, is expected to close in the third quarter of 2026, subject to shareholder and regulatory approvals, after which Esperion will be taken private and delisted from Nasdaq. The structure preserves upside for equity holders through sales-linked CVRs while giving ARCHIMED full control of Esperion’s cardiometabolic franchise, and the company has canceled its previously scheduled first-quarter 2026 earnings call as it pivots operational focus to completing the transaction.

The most recent analyst rating on (ESPR) stock is a Hold with a $3.16 price target. To see the full list of analyst forecasts on Esperion stock, see the ESPR Stock Forecast page.

Spark’s Take on ESPR Stock

According to Spark, TipRanks’ AI Analyst, ESPR is a Neutral.

The score is held back primarily by weak financial durability (negative equity, ongoing losses, and negative free cash flow) and bearish-to-neutral technicals. Offsetting these, the latest earnings call and corporate developments point to improving operating momentum, clearer 2026 planning, and portfolio expansion via the Corstasis/Enbumyst deal, though one-time 2025 revenue benefits and higher expense needs temper the upside.

To see Spark’s full report on ESPR stock, click here.

More about Esperion

Esperion Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing and delivering cardiometabolic and rare/orphan disease therapies. The Ann Arbor-based group markets two oral, once-daily non-statin LDL-C-lowering drugs, leverages ACLY biology, and operates a broad U.S. commercial infrastructure with approvals in more than 40 countries.

This positioning has made Esperion a partner-of-choice for innovators seeking U.S. market access via acquisitions, in-licenses, co-promotions and revenue sharing arrangements. The company is also building a diversified pipeline targeting conditions such as Primary Sclerosing Cholangitis and renal diseases, aiming to expand its role in cardiovascular and primary care markets.

Average Trading Volume: 5,626,672

Technical Sentiment Signal: Sell

Current Market Cap: $514.8M

See more insights into ESPR stock on TipRanks’ Stock Analysis page.